Freezing oocytes or embryos after controlled ovarian hyperstimulation in cancer patients: the state of the art

Papers of special note have been highlighted as: •• of considerable interest

References

• 1 Practice Committees of American Society for Reproductive Medicine, Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil. Steril. 99(1), 37–43 (2013).
  MedlineGoogle Scholar
• 2 Schmidt KT, Andersen CY. ISFP Practice Committee. Recommendations for fertility preservation in patients with lymphomas. J. Assist. Reprod. Genet. 29(6), 473–477 (2012).
  MedlineGoogle Scholar
• 3 Kim SS, Donnez J, Barri P et al. Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancer. J. Assist. Reprod. Genet. 29(6), 465–468 (2012).
  MedlineGoogle Scholar
• 4 Loren AW, Mangu PB, Beck LN et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 31(19), 2500–2510 (2013).
  MedlineGoogle Scholar
• 5 McGee EA, Hsueh AJ. Initial and cyclic recruitment of ovarian follicles. Endocr. Rev. 21(2), 200–214 (2000).
  Medline CASGoogle Scholar
• 6 Baker TG. A quantitative and cytological study of germ cells in human ovaries. Proc. R. Soc. Lond. B Biol. Sci. 158, 417–433 (1963).
  Medline CASGoogle Scholar
• 7 Baerwald AR, Adams GP, Pierson RA. A new model for ovarian follicular development during the human menstrual cycle. Fertil. Steril. 80(1), 116–122 (2003).
  MedlineGoogle Scholar
• 8 Fauser BC, Van Heusden AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr. Rev. 18(1), 71–106 (1997).
  Medline CASGoogle Scholar
• 9 Verberg MFG, Macklon NS, Nargund G et al. Mild ovarian stimulation for IVF. Hum. Reprod. Update 15(1), 13–29 (2009).
  Medline CASGoogle Scholar
• 10 Schipper I, de Jong FH, Fauser BC. Lack of correlation between maximum early follicular phase serum follicle stimulating hormone concentrations and menstrual cycle characteristics in women under the age of 35 years. Hum. Reprod. Oxf. Engl. 13(6), 1442–1448 (1998).
  Medline CASGoogle Scholar
• 11 van Rooij IAJ, Broekmans FJM, te Velde ER et al. Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum. Reprod. Oxf. Engl. 17(12), 3065–3071 (2002).
  Medline CASGoogle Scholar
• 12 Broer SL, Mol BWJ, Hendriks D, Broekmans FJM. The role of antiMullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil. Steril. 91(3), 705–714 (2009).
  Medline CASGoogle Scholar
• 13 Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum. Reprod. Update. 12(6), 685–718 (2006).
  Medline CASGoogle Scholar
• 14 Lee S, Ozkavukcu S, Heytens E, Moy F, Alappat RM, Oktay K. Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone. J. Assist. Reprod. Genet. 28(7), 651–656 (2011).
  MedlineGoogle Scholar
• 15 Friedler S, Koc O, Gidoni Y, Raziel A, Ron-El R. Ovarian response to stimulation for fertility preservation in women with malignant disease: a systematic review and meta-analysis. Fertil. Steril. 97(1), 125–133 (2012).
  MedlineGoogle Scholar
• 16 Domingo J, Guillén V, Ayllón Y et al. Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. Fertil. Steril. 97(4), 930–934 (2012).
  MedlineGoogle Scholar
• 17 Lee S, Oktay K. Does higher starting dose of FSH stimulation with letrozole improve fertility preservation outcomes in women with breast cancer? Fertil. Steril. 98(4), 961–964.e1 (2012).
  Medline CASGoogle Scholar
• 18 Quintero RB, Helmer A, Huang JQ, Westphal LM. Ovarian stimulation for fertility preservation in patients with cancer. Fertil. Steril. 93(3), 865–868 (2010).
  Medline CASGoogle Scholar
• 19 Agarwal A, Said TM. Implications of systemic malignancies on human fertility. Reprod. Biomed. Online 9(6), 673–679 (2004).
  MedlineGoogle Scholar
• 20 Oktay K, Kim JY, Barad D, Babayev SN. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J. Clin. Oncol. 28(2), 240–244 (2010).
  Medline CASGoogle Scholar
• 21 Johnson LNC, Dillon KE, Sammel MD et al. Response to ovarian stimulation in patients facing gonadotoxic therapy. Reprod. Biomed. Online 26(4), 337–344 (2013).
  Medline CASGoogle Scholar
• 22 Knopman JM, Noyes N, Talebian S, Krey LC, Grifo JA, Licciardi F. Women with cancer undergoing ART for fertility preservation: a cohort study of their response to exogenous gonadotropins. Fertil. Steril. 91(4 Suppl.), 1476–1478 (2009).
  MedlineGoogle Scholar
• 23 Robertson AD, Missmer SA, Ginsburg ES. Embryo yield after in vitro fertilization in women undergoing embryo banking for fertility preservation before chemotherapy. Fertil. Steril. 95(2), 588–591 (2011).
  MedlineGoogle Scholar
• 24 Cardozo ER, Thomson AP, Karmon AE, Dickinson KA, Wright DL, Sabatini ME. Ovarian stimulation and in-vitro fertilization outcomes of cancer patients undergoing fertility preservation compared with age matched controls: a 17-year experience. J. Assist. Reprod. Genet. 32(4), 587–596 (2015).
  MedlineGoogle Scholar
• 25 Devesa M, Martínez F, Coroleu B, Rodríguez I, González C, Barri PN. Ovarian response to controlled ovarian hyperstimulation in women with cancer is as expected according to an age-specific nomogram. J. Assist. Reprod. Genet. 31(5), 583–588 (2014).
  MedlineGoogle Scholar
• 26 van Dorp W, van den Heuvel-Eibrink MM, de Vries ACH et al. Decreased serum anti-Müllerian hormone levels in girls with newly diagnosed cancer. Hum. Reprod. Oxf. Engl. 29(2), 337–342 (2014).
  Medline CASGoogle Scholar
• 27 Lawrenz B, Fehm T, von Wolff M et al. Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma – evaluation by using antimüllerian hormone and retrieved oocytes. Fertil. Steril. 98(1), 141–144 (2012).
  Medline CASGoogle Scholar
• 28 Tulandi T, Holzer H. Effects of malignancies on the gonadal function. Fertil. Steril. 98(4), 813–815 (2012).
  MedlineGoogle Scholar
• 29 Pavone ME, Hirshfeld-Cytron J, Lawson AK, Smith K, Kazer R, Klock S. Fertility preservation outcomes may differ by cancer diagnosis. J. Hum. Reprod. Sci. 7(2), 111–118 (2014).
  MedlineGoogle Scholar
• 30 Dolmans MM, Hollanders de Ouderaen S, Demylle D, Pirard C. Utilization rates and results of long-term embryo cryopreservation before gonadotoxic treatment. J. Assist. Reprod. Genet. 32(8), 1233–1237 (2015).
  Medline CASGoogle Scholar
• 31 Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum. Reprod. Oxf. Engl. 26(7), 1768–1774 (2011).
  MedlineGoogle Scholar
• 32 Stoop D, Cobo A, Silber S. Fertility preservation for age-related fertility decline. Lancet. 384(9950), 1311–1319 (2014).
  MedlineGoogle Scholar
• 33 Doyle JO, Richter KS, Lim J, Stillman RJ, Graham JR, Tucker MJ. Successful elective and medically indicated oocyte vitrification and warming for autologous in vitro fertilization, with predicted birth probabilities for fertility preservation according to number of cryopreserved oocytes and age at retrieval. Fertil. Steril. 105(2), 459–466.e2 (2016).
  MedlineGoogle Scholar
• 34 Bedoschi GM, de Albuquerque FO, Ferriani RA, Navarro PA. Ovarian stimulation during the luteal phase for fertility preservation of cancer patients: case reports and review of the literature. J. Assist. Reprod. Genet. 27(8), 491–494 (2010).
  MedlineGoogle Scholar
• 35 Sönmezer M, Türkçüoğlu I, Coşkun U, Oktay K. Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil. Steril. 95(6), 2125.e9–11 (2011).
  Google Scholar
• 36 von Wolff M, Thaler CJ, Frambach T et al. Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil. Steril. 92(4), 1360–1365 (2009).
  Medline CASGoogle Scholar
• 37 Bosch E, Labarta E, Crespo J et al. Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles. Hum. Reprod. Oxf. Engl. 25(8), 2092–2100 (2010).
  Medline CASGoogle Scholar
• 38 Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil. Steril. 100(6), 1673–1680 (2013). •• This investigation confirms the possibility of starting ovarian stimulation whatever the phase of menstrual cycle.
  MedlineGoogle Scholar
• 39 Humaidan P, Bungum L, Bungum M et al. Reproductive outcome using a GnRH antagonist (cetrorelix) for luteolysis and follicular synchronization in poor responder IVF/ICSI patients treated with a flexible GnRH antagonist protocol. Reprod. Biomed. Online 11(6), 679–684 (2005).
  Medline CASGoogle Scholar
• 40 Kuang Y, Chen Q, Hong Q et al. Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol). Reprod. Biomed. Online 29(6), 684–691 (2014).
  MedlineGoogle Scholar
• 41 Turan V, Bedoschi G, Moy F, Oktay K. Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients. Fertil. Steril. 100(6), 1681–1685.e1 (2013).
  Medline CASGoogle Scholar
• 42 Cahill DJ, Wardle PG, Harlow CR, Hunt LP, Hull MG. Expected contribution to serum oestradiol from individual ovarian follicles in unstimulated cycles. Hum. Reprod. Oxf. Engl. 15(9), 1909–1912 (2000).
  Medline CASGoogle Scholar
• 43 Gupta PB, Kuperwasser C. Contributions of estrogen to ER-negative breast tumor growth. J. Steroid Biochem. Mol. Biol. 102(1–5), 71–78 (2006).
  Medline CASGoogle Scholar
• 44 Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J. Clin. Oncol. 26(16), 2630–2635 (2008).
  Medline CASGoogle Scholar
• 45 Goldrat O, Kroman N, Peccatori FA et al. Pregnancy following breast cancer using assisted reproduction and its effect on long-term outcome. Eur. J. Cancer Oxf. Engl. 51(12), 1490–1496 (2015).
  MedlineGoogle Scholar
• 46 Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil. Steril. 75(2), 305–309 (2001).
  Medline CASGoogle Scholar
• 47 Sharma S, Ghosh S, Singh S et al. Congenital malformations among babies born following letrozole or clomiphene for infertility treatment. PLoS ONE 9(10), e108219 (2014).
  MedlineGoogle Scholar
• 48 Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J. Clin. Oncol. 23(19), 4347–4353 (2005).
  Medline CASGoogle Scholar
• 49 Oktay K, Hourvitz A, Sahin G et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J. Clin. Endocrinol. Metab. 91(10), 3885–3890 (2006). •• This study has shown for the first time the feasibility of combining exogenous follicle-stimulating hormone administration with others drugs, to enable follicular growth while maintaining normal serum estradiol concentrations.
  Medline CASGoogle Scholar
• 50 Oktay K, Türkçüoğlu I, Rodriguez-Wallberg KA. GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod. Biomed. Online 20(6), 783–788 (2010).
  Medline CASGoogle Scholar
• 51 Oktay K, Hourvitz A, Sahin G et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J. Clin. Endocrinol. Metab. 91(10), 3885–3890 (2006).
  Medline CASGoogle Scholar
• 52 Oktay K, Turan V, Bedoschi G, Pacheco FS, Moy F. Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer. J. Clin. Oncol. 33(22), 2424–2429 (2015).
  MedlineGoogle Scholar
• 53 Kim J, Turan V, Oktay K. Long-term safety of letrozone and gonadotropin stimulation for fertility preservation in women with breast cancer. J. Clin. Endocrinol. Metab. 101(4), 1364–1371 (2016).
  Medline CASGoogle Scholar
• 54 Oktay K, Turan V, Bedoschi G, Pacheco FS, Moy F. Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer. J. Clin. Oncol. 33(22), 2424–2429 (2015).
  MedlineGoogle Scholar
• 55 Azim A, Oktay K. Letrozole for ovulation induction and fertility preservation by embryo cryopreservation in young women with endometrial carcinoma. Fertil. Steril. 88(3), 657–664 (2007).
  Medline CASGoogle Scholar
• 56 Meirow D, Raanani H, Maman E et al. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies. Fertil. Steril. 102(2), 488–495.e3 (2014).
  Medline CASGoogle Scholar
• 57 Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum. Reprod. Update 8(6), 559–577 (2002).
  Medline CASGoogle Scholar
• 58 Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil. Steril. 89(1), 84–91 (2008).
  Medline CASGoogle Scholar
• 59 Reddy J, Turan V, Bedoschi G, Moy F, Oktay K. Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience. J. Assist. Reprod. Genet. 31(7), 927–932 (2014).
  MedlineGoogle Scholar
• 60 Oktay K, Türkçüoğlu I, Rodriguez-Wallberg KA. GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod. Biomed. Online 20(6), 783–788 (2010).
  Medline CASGoogle Scholar
• 61 Youssef MA, Van der Veen F, Al-Inany HG, Griesinger G, Mochtar MH, van Wely M. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database Syst. Rev. (11), CD008046 (2010).
  MedlineGoogle Scholar
• 62 Kolibianakis EM, Schultze-Mosgau A, Schroer A et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum. Reprod. Oxf. Engl. 20(10), 2887–2892 (2005).
  Medline CASGoogle Scholar
• 63 Acevedo B, Gomez-Palomares JL, Ricciarelli E, Hernández ER. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil. Steril. 86(6), 1682–1687 (2006).
  Medline CASGoogle Scholar
• 64 Erb TM, Vitek W, Wakim ANG. Gonadotropin-releasing hormone agonist or human chorionic gonadotropin for final oocyte maturation in an oocyte donor program. Fertil. Steril. 93(2), 374–378 (2010).
  Medline CASGoogle Scholar
• 65 Bodri D, Guillén JJ, Galindo A, Mataró D, Pujol A, Coll O. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. Fertil. Steril. 91(2), 365–371 (2009).
  Medline CASGoogle Scholar
• 66 Humaidan P, Bredkjaer HE, Bungum L et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum. Reprod. Oxf. Engl. 20(5), 1213–1220 (2005).
  Medline CASGoogle Scholar
• 67 Caine GJ, Stonelake PS, Lip GYH, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 4(6), 465–473 (2002).
  Medline CASGoogle Scholar
• 68 Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb. Res. 125(6), 490–493 (2010).
  Medline CASGoogle Scholar
• 69 Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med. 9(7), e1001275 (2012).
  MedlineGoogle Scholar
• 70 Previtali E, Bucciarelli P, Passamonti SM, Martinelli I. Risk factors for venous and arterial thrombosis. Blood Transfus. Trasfus. Sangue 9(2), 120–138 (2011).
  MedlineGoogle Scholar
• 71 Barcroft J, Dayoub N, Thong KJ. Fifteen year follow-up of embryos cryopreserved in cancer patients for fertility preservation. J. Assist. Reprod. Genet. 30(11), 1407–1413 (2013).
  Medline CASGoogle Scholar
• 72 Garcia-Velasco JA, Domingo J, Cobo A, Martínez M, Carmona L, Pellicer A. Five years’ experience using oocyte vitrification to preserve fertility for medical and nonmedical indications. Fertil. Steril. 99(7), 1994–1999 (2013).
  MedlineGoogle Scholar
• 73 Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293(6), 715–722 (2005).
  Medline CASGoogle Scholar
• 74 Chan WS. The ‘ART’ of thrombosis: a review of arterial and venous thrombosis in assisted reproductive technology. Curr. Opin. Obstet. Gynecol. 21(3), 207–218 (2009).
  MedlineGoogle Scholar
• 75 Chan WS, Dixon ME. The ‘ART’ of thromboembolism: a review of assisted reproductive technology and thromboembolic complications. Thromb. Res. 121(6), 713–726 (2008).
  Medline CASGoogle Scholar
• 76 Fatemi HM, Popovic-Todorovic B, Humaidan P et al. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and ‘freeze-all’ approach in GnRH antagonist protocol. Fertil. Steril. 101(4), 1008–1011 (2014).
  Medline CASGoogle Scholar
• 77 Reichman DE, Davis OK, Zaninovic N, Rosenwaks Z, Goldschlag DE. Fertility preservation using controlled ovarian hyperstimulation and oocyte cryopreservation in a premenarcheal female with myelodysplastic syndrome. Fertil. Steril. 98(5), 1225–1228 (2012).
  MedlineGoogle Scholar